Decheng Capital LLC Buys Shares of 2,266,667 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Decheng Capital LLC bought a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,266,667 shares of the biotechnology company's stock, valued at approximately $5,621,000. Aclaris Therapeutics makes up about 1.2% of Decheng Capital LLC's holdings, making the stock its 17th biggest position. Decheng Capital LLC owned approximately 3.17% of Aclaris Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. purchased a new stake in Aclaris Therapeutics in the fourth quarter worth $23,876,000. Vivo Capital LLC bought a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $22,044,000. Rock Springs Capital Management LP lifted its holdings in Aclaris Therapeutics by 125.3% in the fourth quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company's stock worth $15,387,000 after buying an additional 3,450,814 shares during the period. Marshall Wace LLP bought a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $6,532,000. Finally, Walleye Capital LLC purchased a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $1,783,000. Hedge funds and other institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock traded down $0.02 during mid-day trading on Thursday, reaching $1.37. The stock had a trading volume of 164,601 shares, compared to its average volume of 1,183,602. The company has a market capitalization of $147.80 million, a price-to-earnings ratio of -2.63 and a beta of 0.53. The company has a 50-day moving average price of $1.51 and a two-hundred day moving average price of $2.23. Aclaris Therapeutics, Inc. has a one year low of $0.95 and a one year high of $5.17.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Scotiabank assumed coverage on Aclaris Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an "overweight" rating on the stock. Finally, StockNews.com downgraded shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Aclaris Therapeutics has an average rating of "Moderate Buy" and an average target price of $11.67.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.